Literature DB >> 7438538

The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations.

S A Cairns, A London, N P Mallick.   

Abstract

Sixteen patients with systemic lupus erythematosus, fourteen with renal involvement have been studied over a 30-month period. Circulating immune complex levels have been assayed by three techniques. The results of tests on 141 sequential sera suggest that the three assays detected overlapping populations of the range of complexes present. Immune complex levels are shown to be good markers of disease activity and certain immunochemical properties of the complexes emerged as better markers than others. Immune complex size is a more important determinant of disease manifestation than are overall immune complex levels. High doses of intravenous methyl prednisolone, which did not reduce overall complex levels, reduced levels of those complexes (molecular weight 600,000-900,000 Daltons) associated with renal involvement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438538      PMCID: PMC1536977     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.

Authors:  J S Cameron; M H Lessof; C S Ogg; B D Williams; D G Williams
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

2.  Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations.

Authors:  A Cruchaud; F Chenais; G J Fournié; L Humair; P H Lambert; J C Mulli; F Chatelanat
Journal:  Eur J Clin Invest       Date:  1975-06-12       Impact factor: 4.686

3.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

Review 4.  Immune complex disease in experimental animals and man.

Authors:  C G Cochrane; D Koffler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies.

Authors:  K Yonemasu; R M Stroud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

7.  Measurement of serum DNA-binding activity in systemic lupus erythematosus.

Authors:  T Pincus; P H Schur; J A Rose; J L Decker; N Talal
Journal:  N Engl J Med       Date:  1969-09-25       Impact factor: 91.245

8.  Serum immune complexes and disease activity in lupus nephritis.

Authors:  R J Levinsky; J S Cameron; J F Soothill
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

9.  Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis.

Authors:  E S Cathcart; B A Idelson; M A Scheinberg; W G Couser
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321

10.  Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes.

Authors:  S Izui; P H Lambert; G J Fournié; H Türler; P A Miescher
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

View more
  7 in total

1.  C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases.

Authors:  C Huber; A Rüger; M Herrmann; F Krapf; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  Influence of immune complex lattice on the C1q solid phase assay as determined with covalently cross-linked immune complexes.

Authors:  M H Wener; M Mannik
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

3.  Neutrophil activation by immune complexes and the role of rheumatoid factor.

Authors:  R Gale; J V Bertouch; T P Gordon; J Bradley; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

4.  Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).

Authors:  N P Hurst; G Nuki; T Wallington
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

5.  Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; C M Tseng; I E Coremans; L A van Es; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

6.  Detection of DNA-bound immunoglobulins in patients with lupus nephritis, using monoclonal anti-DNA antibody.

Authors:  A Koyama; M Kobayashi; S Suzuki; M Suzuki; N Yamaguchi; M Narita
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

7.  A simple quantitative assay of circulating immune complexes by laser nephelometry, using a rabbit igg antibody against human aggregated igg.

Authors:  K Arai; A Shimizu
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.